Top Page
Arovella Therapeutics Limited
(Sydney:ALA)
Arovella Therapeutics Limited (ALA) vs. iShares MSCI Australia ETF (EWA)
Arovella Therapeutics Limited Business Overview & Revenue Model
Arovella Therapeutics Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -3.30M | 136.00K | 17.00K | 405.90K | 295.81K | 257.35K |
| Gross Profit | -3.36M | 136.00K | -25.98K | -3.00M | 88.75K | 34.60K |
| EBITDA | -14.93M | -11.10M | -10.63M | -10.37M | -7.87M | -4.99M |
| Net Income | -7.93M | -7.51M | -8.75M | -10.18M | -8.62M | -5.05M |
Balance Sheet | ||||||
| Total Assets | 20.25M | 21.60M | 13.28M | 5.47M | 9.21M | 10.69M |
| Cash, Cash Equivalents and Short-Term Investments | 19.37M | 20.88M | 12.71M | 5.18M | 6.07M | 6.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 144.80K | 144.80K | 79.23K |
| Total Liabilities | 1.33M | 1.52M | 2.06M | 1.69M | 1.60M | 1.71M |
| Stockholders Equity | 18.92M | 20.08M | 11.23M | 3.78M | 7.62M | 8.98M |
Cash Flow | ||||||
| Free Cash Flow | -6.93M | -7.34M | -7.04M | -6.40M | -6.83M | -4.06M |
| Operating Cash Flow | -6.82M | -6.93M | -6.91M | -6.40M | -6.27M | -3.54M |
| Investing Cash Flow | -122.36K | -432.11K | -179.34K | 95.42K | -566.00K | -514.55K |
| Financing Cash Flow | 14.59M | 15.52M | 14.61M | 5.41M | 6.19M | 9.80M |
Arovella Therapeutics Limited Technical Analysis
Arovella Therapeutics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$72.45M | 25.12 | 27.24% | 2.81% | 0.65% | -9.90% | |
52 Neutral | AU$98.99M | -11.71 | -47.98% | ― | 700.00% | 26.88% | |
52 Neutral | AU$156.16M | -4.74 | ― | ― | ― | 0.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | AU$61.57M | -5.97 | -27.39% | ― | ― | 26.64% | |
41 Neutral | AU$87.00M | -6.67 | -42.68% | ― | ― | 63.46% | |
41 Neutral | AU$56.16M | -5.40 | -71.87% | ― | 7.65% | -19.13% |
Arovella Therapeutics Limited Corporate Events
Arovella Therapeutics Limited has disclosed that director Gary Phillips ceased to be a director of the company on 9 February 2026. The filing notes that at the time of his departure, Phillips held indirect interests comprising 788,888 fully paid ordinary shares and 3,732,000 options in the company.
The notice confirms that Phillips had no directly registered shareholdings or contractual interests disclosed at the time of cessation. This change in the board’s composition may be of interest to shareholders monitoring governance, leadership stability and potential future strategic direction at Arovella Therapeutics.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics has announced the retirement of Interim Chair and Non-Executive Director Dr Elizabeth Stoner and Non-Executive Director Gary Phillips, both effective 9 February 2026. In response to these significant board changes, the company will undertake a skills review and subsequently appoint a new Chair.
Chief executive Dr Michael Baker credited Stoner and Phillips with guiding Arovella through its pivot to a cell therapy focus and helping advance its CAR-iNKT platform from preclinical to IND-ready status. With the recent acceptance of the IND for lead candidate ALA-101 and ongoing work on solid tumour program ALA-105, the company emphasised that the board transition comes as it prepares to dose its first patient and strengthen governance capabilities for its next phase of growth.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics announced that CEO and Managing Director Dr Michael Baker is presenting at the Euroz Hartleys 2026 Healthcare Forum in Perth and will conduct a non-deal investor roadshow across Perth, Sydney and Melbourne from 5–10 February. The company has released updated investor presentations via the ASX and its website, using the forum and meetings to deepen engagement with the investment community and highlight progress on its iNKT cell therapy platform and oncology pipeline, potentially supporting broader market visibility and future capital markets activity.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics has become a clinical‑stage company after the US Food and Drug Administration accepted its Investigational New Drug application for ALA-101, a CAR-iNKT cell therapy for patients with CD19-positive lymphoma and leukaemia, clearing the way for a Phase 1 trial in 2026. The company says this IND validates four years of work on a proprietary CAR‑iNKT manufacturing process that can be reused across multiple products, potentially becoming a key value driver as Arovella broadens its pipeline into solid tumours, including CLDN18.2‑targeted programs for gastric and pancreatic cancers and new GD2 and GPC3 CAR assets licensed from Baylor College of Medicine. Over 2025 Arovella also strengthened its clinical and scientific capabilities with senior hires, a new laboratory and a sponsored research agreement with the University of North Carolina, while adding veteran drug developer Andrew Nash to its board with a view to him becoming chairman. Backed by $19.4 million in cash at year-end 2025, the company says it is funded to reach early safety and efficacy readouts for ALA-101 and to advance additional candidates such as ALA-105, underlining its ambition to secure a stronger position in the competitive cell therapy market.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics has received U.S. Food and Drug Administration acceptance of its investigational new drug application for ALA-101, clearing the way for first-in-human Phase 1 trials in patients with relapsed or refractory CD19-positive non-Hodgkin’s lymphoma and leukaemia. The FDA decision validates ALA-101’s preclinical, manufacturing and development plans, de-risks the program, and enables Arovella to run its initial trial more efficiently in Australia under the CTN scheme while also opening sites in the U.S., creating a regulatory framework that can be leveraged for follow-on CAR-iNKT candidates such as ALA-105 and other solid tumour programs, thereby strengthening the company’s position in next-generation allogeneic cell therapies and potentially accelerating patient access to off-the-shelf treatments.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics reported progress in the second quarter of FY26, highlighted by the filing of an Investigational New Drug application with the U.S. FDA for its lead allogeneic CAR-iNKT candidate ALA-101, selection of CRO SAPRO to run a first-in-human phase 1 trial in CD19-positive lymphoma and leukaemia across Australia and New Zealand, and confirmation of potent activity for its CLDN18.2-targeting CAR within the ALA-105 solid tumour program. The company ended the quarter with $19.4 million in cash, which it expects will fund completion of ALA-101 phase 1 enrolment and advancement of its solid tumour and armouring programs, while the in-licensing of additional CAR and iNKT-related technologies from Baylor College of Medicine and the board appointment of experienced drug developer Dr Andrew Nash are intended to strengthen its technology base, clinical transition and strategic positioning as it moves toward becoming a clinical-stage cell therapy player in 2026.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics has appointed Lachie Mallia as Company Secretary and Chief Financial Officer, effective 22 January 2026, replacing fellow Bio101 Financial Advisory director Tim Luscombe, who previously held the roles. Mallia, a director at Bio101 with extensive experience providing outsourced CFO, company secretarial and advisory services to healthcare companies, will oversee ASX communications on listing rule matters, bolstering Arovella’s governance and financial management as it advances its oncology cell therapy pipeline.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics has announced that 936,303 ordinary shares, issued on 4 August 2025 as non-cash consideration for investor relations services, will be released from voluntary escrow on 31 January 2026. The move modestly increases the company’s freely tradable share float, potentially enhancing liquidity in its stock while reflecting the use of equity-based payments to support its investor engagement activities.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
Arovella Therapeutics has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for its lead allogeneic CAR-iNKT cell therapy candidate, ALA-101, targeting CD19-positive non-Hodgkin’s lymphoma and leukaemias. Clearance of the application would enable the company to launch a first-in-human Phase 1 trial in relapsed or refractory CD19-positive blood cancers, with trial sites planned in both Australia and the United States under a more efficient regulatory pathway, marking Arovella’s transition toward becoming a clinical-stage biotech and potentially strengthening its position in the competitive cell therapy market.
Arovella Therapeutics Limited has issued 371,187 ordinary shares without disclosure under the Corporations Act, complying with relevant legal provisions. This move is part of the company’s strategic efforts to strengthen its financial position and support its ongoing development of innovative cancer therapies, potentially enhancing its market presence and stakeholder value.
Arovella Therapeutics Limited has announced the quotation of 371,187 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of an employee incentive scheme. This move is likely to enhance the company’s market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder interests positively.